|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Marketed
Products
Twenty-three (23) products incorporating EDT technologies
are currently marketed by EDT licensees, and EDT receives
royalties and, in some cases, manufacturing fees on these,
including:
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Marketed
Products
22 products that incorporate EDT technologies are currently
marketed by EDT licensees, and on which EDT receives royalties
and in some cases manufacturing fees, including:
Table of Contents
This excerpt taken from the ELN 20-F filed Mar 30, 2006. (A) Marketed
products
Total revenue from marketed products increased to
$174.5 million in 2004 from $154.2 million in 2003.
The increase of 13% primarily reflected the growth in
prescriptions and demand for Maxipime and Azactam,
and initial sales of Tysabri. The basic patent on
Maxipime expires in March 2007 and the basic patent on
Azactam expired in October 2005. Two U.S. patents
covering Maxipime formulations may provide patent
protection until 2008. The expiration of these patents is
expected to result in generic competition for these products,
which could adversely impact future revenues. To date no
Azactam generic has been approved.
As reported by IMS Health National Sales Perspectives,
Maxipime prescription demand for 2004 increased by 14%
over 2003, while revenues increased from $109.1 million to
$117.5 million, or 8%. Azactam prescription demand
for 2004 increased by 12% over the same period in 2003,
corresponding to increased revenues from $45.1 million to
$50.6 million. The difference between prescription and
revenue growth rates is due to changing wholesaler inventory
levels.
The FDA granted accelerated approval of Tysabri in late
November 2004 for the treatment of patients in the United States
with all forms of relapsing remitting MS. Revenue from
Tysabri amounted to $6.4 million in 2004. The
marketing and clinical dosing of Tysabri was voluntarily
suspended in February 2005. On March 7-8, 2006, the PCNS
Advisory Committee reviewed and voted unanimously to recommend
that Tysabri be reintroduced as a treatment for relapsing
forms of MS. On March 21, 2006, we and Biogen Idec were
informed by the FDA that the agency would extend its regulatory
review of Tysabri by up to 90 days in order to
complete a full review of the
Table of Contents
Tysabri risk management plan. Under the revised timeline,
we anticipate an action from the FDA about the reintroduction of
Tysabri as a treatment for relapsing forms of MS on or
before June 28, 2006.
| EXCERPTS ON THIS PAGE:
|
| |||||||
